Postmenopausal Bleeding Is Never "Just Hormones"

By Daniel Soule, Owner and Clinic Director, HormoneSynergy®

One of the more concerning conversations in menopause care begins with a sentence clinicians hear often: “I assumed it was just my hormones.”

Hormone therapy can affect bleeding patterns, particularly when treatment is started or adjusted. Vaginal and endometrial atrophy, uterine polyps, fibroids, and other benign conditions can also cause spotting. Most women evaluated for postmenopausal bleeding will not have cancer.

Bleeding after menopause can also be the first sign of endometrial cancer. It should not be attributed to estrogen, progesterone, a missed dose, or a recent adjustment until the cause has been appropriately considered.

What Counts as Postmenopausal Bleeding?

Natural menopause is generally recognized after twelve consecutive months without a menstrual period when there is no other explanation for the absence of bleeding.

After that point, postmenopausal bleeding can be light enough to appear only on toilet tissue. It may look pink, red, rust-colored, or brown. It may occur after sex, resemble a light period, or happen once and then stop.

A single episode still deserves a call to the clinician managing the patient’s care. The amount of blood does not reliably identify the cause, and neither does the fact that it stopped on its own.

Women using a planned cyclic hormone regimen may have an expected withdrawal bleed. That is different from bleeding that is new, prolonged, unusually heavy, begins after a previously stable pattern, or continues outside the anticipated schedule. The prescription and timing need to be reviewed rather than applying one rule to every hormone regimen.

Most Causes Are Benign, but the Cause Still Needs to Be Found

Thinning of the vaginal or uterine tissues is a common cause of bleeding after menopause. Polyps, fibroids, cervical changes, infection, trauma, and medication effects may also be responsible.

Endometrial hyperplasia and endometrial cancer are less common, but they are the diagnoses the evaluation cannot afford to miss. According to the American College of Obstetricians and Gynecologists, vaginal bleeding is the presenting sign in more than 90 percent of postmenopausal women with endometrial cancer.

Early endometrial cancer is often highly treatable. Its tendency to produce bleeding while the disease is still confined to the uterus is one reason prompt evaluation can make such a difference.

Estrogen, Progesterone, and the Uterine Lining

Estrogen stimulates the endometrium, the tissue lining the inside of the uterus. During the reproductive years, progesterone helps organize and limit that growth after ovulation.

A postmenopausal woman who still has a uterus and uses systemic estrogen generally needs an adequate progestogen to protect the endometrium. That may be micronized progesterone, an appropriate synthetic progestin, or another medically established form of protection selected for the individual patient.

Systemic estrogen used without adequate endometrial protection increases the risk of endometrial hyperplasia and cancer. The risk is influenced by the estrogen dose, duration of exposure, the progesterone or progestogen regimen, adherence, and the patient’s underlying risk factors.

Prescribing progesterone is not enough by itself. The route, dose, schedule, and reliability of absorption matter. Transdermal progesterone creams have not been shown to provide dependable protection of the uterine lining when systemic estrogen is used. A cream that helps someone sleep or produces a measurable hormone level should not automatically be assumed to protect the endometrium.

Dr. Kathryn Retzler has taught this distinction for years: progesterone is not merely an optional calming hormone added to estrogen. In a woman with an intact uterus, it may have a specific safety role in the treatment plan. Hormone therapy should be designed around that responsibility from the beginning.

Too Much Estrogen Is Not Defined by One Laboratory Number

The phrase “too much estrogen” is often used loosely. A blood level does not tell the entire endometrial story, particularly with transdermal, oral, vaginal, pellet, or compounded delivery systems that behave differently.

The more clinically useful questions are whether the estrogen dose is appropriate for the indication, whether the patient has a uterus, whether endometrial protection is adequate, whether medications are being taken consistently, and whether bleeding has occurred.

Escalating estrogen repeatedly in pursuit of a target number or a promise of anti-aging benefit can expose a patient to unnecessary risk. So can leaving a high-dose implant or pellet in place while assuming that a small amount of progesterone will balance it.

Hormone treatment should use the lowest effective dose consistent with the patient’s goals and clinical needs. Symptoms, adverse effects, medical history, physical findings, and selective testing are considered together. Laboratory values may help in some situations, but they do not replace clinical judgment or evaluation of bleeding.

Bleeding During Hormone Therapy

Some bleeding can occur during the first months of continuous combined menopausal hormone therapy or after a change in dose or formulation. Sequential therapy is intentionally designed to produce a scheduled withdrawal bleed.

That does not give every episode of bleeding a free pass. The timing, pattern, heaviness, treatment regimen, and patient’s risk profile need to be reviewed.

Bleeding that begins after a woman has been stable and bleed-free, continues beyond the expected adjustment period, becomes heavy or prolonged, or returns after an earlier reassuring evaluation generally warrants investigation. The threshold for evaluation should be lower when risk factors for endometrial cancer are present.

Changing progesterone or reducing estrogen may eventually be part of the treatment. It should not be used as a substitute for evaluating bleeding when evaluation is indicated.

What Proper Hormone-Therapy Monitoring Looks Like

Good hormone care is a follow-up relationship, not a prescription transaction. Monitoring is individualized, but it begins with knowing exactly what the patient is taking and whether she still has a uterus.

Follow-up commonly includes:

• Review of bleeding, spotting, discharge, pelvic discomfort, and breast symptoms
• Confirmation of the estrogen dose, route, and treatment schedule
• Confirmation of the progesterone or progestogen dose, route, schedule, and adherence
• Review of compounded products, pellets, vaginal preparations, and over-the-counter hormone creams
• Assessment of blood pressure, weight, metabolic health, cardiovascular risk, and new medical diagnoses
• Coordination of age-appropriate breast, cervical, bone, and general preventive care
• Laboratory testing when it will answer a clinical question or guide safe dosing
• Pelvic imaging, endometrial sampling, or gynecology referral when bleeding or other findings warrant it

Routine transvaginal ultrasound is not generally recommended as a screening test for endometrial cancer in an asymptomatic postmenopausal woman solely because she uses hormone therapy. An incidental endometrial measurement in a woman without bleeding is interpreted differently from the same finding in a woman who is bleeding.

Monitoring should be directed by the patient’s treatment and risk, not by a calendar of indiscriminate tests. Once bleeding occurs, however, the evaluation becomes diagnostic rather than routine screening.

Transvaginal Ultrasound Is Often an Appropriate First Test

Transvaginal ultrasound uses a narrow ultrasound probe placed in the vagina to obtain a close view of the uterus, endometrium, ovaries, and surrounding pelvic structures.

It can measure endometrial thickness and may reveal polyps, fibroids, fluid in the uterine cavity, ovarian findings, or an endometrium that is difficult to assess. The examination does not expose the patient to radiation.

For a first episode of postmenopausal bleeding in an appropriately selected woman, either transvaginal ultrasound or endometrial sampling may be used as the initial evaluation. It is not necessary for every patient to have both tests before any clinical judgment can be made.

When a thin, uniform endometrium measuring 4 millimeters or less is clearly visualized, the probability of endometrial cancer is low. ACOG reports that this threshold has a negative predictive value greater than 99 percent for endometrial cancer in women being evaluated for postmenopausal bleeding.

The measurement is reassuring only when the endometrium can be adequately seen and the bleeding does not persist or recur. Ultrasound is less definitive when the lining is thicker than 4 millimeters, irregular, heterogeneous, obscured, or impossible to measure reliably.

When Endometrial Sampling Is Needed

An endometrial biopsy removes a small sample of tissue from inside the uterus so that a pathologist can examine the cells. It may be selected as the initial test when clinical risk is higher or used after ultrasound when the findings are not sufficiently reassuring.

Sampling is commonly considered when:

• The endometrium measures more than 4 millimeters in a woman with postmenopausal bleeding
• The endometrium cannot be fully or reliably visualized
• The ultrasound shows focal thickening, irregularity, or another concerning finding
• Bleeding persists or returns despite a thin endometrial measurement
• The patient has risk factors that make tissue diagnosis more appropriate
• Initial testing does not adequately explain the bleeding

An office biopsy is useful, but it is not perfect. A small sampling device can miss a focal lesion such as a polyp or a localized area of abnormal tissue. An inadequate or benign biopsy does not close the case when bleeding continues.

Why Hysteroscopy May Be Recommended

Hysteroscopy allows a gynecologist to pass a small camera through the cervix and look directly inside the uterine cavity. A polyp or focal abnormality can be seen and sampled rather than relying on a blind tissue specimen.

Dilation and curettage, often called a D&C, may be performed with hysteroscopy when more complete sampling or treatment is needed. The appropriate next step depends on the imaging findings, biopsy result, bleeding pattern, and the patient’s medical circumstances.

Persistent or recurrent bleeding deserves continued evaluation even after an initial ultrasound or biopsy appears reassuring. Rare endometrial cancers can occur with a thin lining, and focal abnormalities may not be captured by a blind biopsy.

Risk Factors That Change the Level of Concern

Endometrial cancer can develop without an obvious risk factor. The likelihood is higher in the presence of certain medical and family-history findings, including:

• Increasing age
• Obesity, particularly excess visceral fat
• Insulin resistance or type 2 diabetes
• Polycystic ovary syndrome or a history of prolonged anovulation
• Long exposure to estrogen without adequate progesterone or progestogen
• Tamoxifen use
• Lynch syndrome or a family history suggesting an inherited cancer syndrome
• A personal history of endometrial hyperplasia
• Earlier menarche, later menopause, or other circumstances associated with greater lifetime estrogen exposure
• Never having carried a pregnancy

Obesity and insulin resistance deserve particular attention. Adipose tissue can contribute to estrogen exposure after menopause, while metabolic dysfunction may promote an environment associated with endometrial cancer risk. This does not mean weight caused an individual woman’s bleeding or cancer. It does mean metabolic health belongs in the larger prevention conversation.

Vaginal Estrogen Is a Different Clinical Situation

Low-dose vaginal estrogen used for genitourinary symptoms generally produces much less systemic exposure than estrogen patches, gels, injections, pellets, or tablets. Most women using standard low-dose local vaginal therapy do not require a progestogen solely because of that treatment.

Bleeding still should not be ignored. Vaginal estrogen may improve fragile tissue and reduce bleeding related to atrophy, but a woman who develops postmenopausal bleeding needs assessment rather than an assumption that the local treatment caused it.

Higher-dose vaginal preparations or compounded products may not have the same exposure profile as established low-dose therapies. The exact product and dose should be reviewed.

When to Seek More Urgent Care

Most postmenopausal bleeding can be evaluated through a timely outpatient appointment. More urgent assessment is appropriate when bleeding is heavy, the patient is soaking pads rapidly, passing large clots, becoming lightheaded or faint, experiencing significant pelvic or abdominal pain, or showing other signs of substantial blood loss or acute illness.

A clinician should also know about anticoagulants and medications that affect bleeding. Those drugs may make bleeding more noticeable, but they do not eliminate the need to identify where it is coming from.

The HormoneSynergy® Perspective

Hormone therapy should not be blamed for every new symptom, and it should not be protected from reasonable scrutiny. Properly prescribed menopausal hormone therapy can be life-changing for the right woman. It can relieve vasomotor symptoms, improve sleep and quality of life, and help prevent bone loss. None of those benefits require us to dismiss uterine safety.

Women with an intact uterus who use systemic estrogen need a credible plan for endometrial protection. They also need to know what bleeding to report, how their regimen is expected to behave, and who will arrange an evaluation when the pattern changes.

Postmenopausal bleeding is not an automatic cancer diagnosis. It is a symptom that deserves an explanation while benign conditions are treatable and endometrial disease, when present, is more likely to be found early.

The answer is not hormone fear. It is careful prescribing, appropriate follow-up, and a willingness to investigate rather than guess.

Related HormoneSynergy® Resources

• Longevity Medicine Resource Library
• Bioidentical Hormone Therapy for Women and Men
• Progesterone Is Not Just “The Sleep Hormone”
• DEXA Bone Density, Visceral Fat and Body Composition Testing

References

1. American College of Obstetricians and Gynecologists. The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. ACOG Committee Opinion No. 734.
2. American College of Obstetricians and Gynecologists. Endometrial Cancer.
3. British Menopause Society. Management of Unscheduled Bleeding on Hormone Replacement Therapy. Joint guideline. 2024.
4. Stute P, Neulen J, Wildt L. The Impact of Micronized Progesterone on the Endometrium: A Systematic Review. Climacteric. 2016;19(4):316–328.
5. The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022.
6. National Cancer Institute. Endometrial Cancer Treatment.

Frequently Asked Questions

Is one episode of bleeding after menopause enough to call my clinician?

Yes. Even light spotting, pink discharge, brown discharge, or an episode that stops should be reported. Most causes are benign, but the pattern cannot be safely diagnosed from the amount or color of blood alone.

Is transvaginal ultrasound the standard first test?

Transvaginal ultrasound is an appropriate initial test for many women with a first episode of postmenopausal bleeding. Endometrial biopsy may also be chosen as the initial test, particularly when risk is higher. The two tests provide different information and are not automatically required together in every patient.

What does an endometrial thickness of 4 millimeters mean?

When the entire endometrium is clearly seen and measures 4 millimeters or less, the risk of endometrial cancer is very low. Persistent or recurrent bleeding still requires further evaluation, even when the lining is thin.

Can hormone therapy cause bleeding after menopause?

Hormone therapy can produce bleeding, especially during the first months of treatment, after a dose change, or with a planned sequential regimen. New, persistent, heavy, recurrent, or otherwise unexpected bleeding should not be attributed to treatment without clinical review.

Do I need progesterone if I use estrogen?

A woman with an intact uterus who uses systemic estrogen generally needs adequate progesterone or another progestogen to reduce the risk of endometrial hyperplasia and cancer. Women who have had a hysterectomy usually do not need progesterone for uterine protection.

Is progesterone cream enough to protect the uterus?

Transdermal progesterone cream is not considered dependable endometrial protection for a woman using systemic estrogen. The prescribed molecule, dose, route, and schedule all need to provide established protection.

Should every woman on hormone therapy have a yearly pelvic ultrasound?

Routine ultrasound screening is not generally recommended solely because an asymptomatic woman is using hormone therapy. Ultrasound becomes appropriate when symptoms, examination findings, treatment history, or other clinical concerns warrant it.

Can a normal biopsy be the end of the evaluation?

It may be sufficient when the tissue sample is adequate and the bleeding resolves. Persistent or recurrent bleeding may require hysteroscopy or additional evaluation because a blind office biopsy can miss focal abnormalities.